GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsGUANGZHOU, and BEIJING, China and CAMBRIDGE, Mass, Aug 24, 2020 – Bio-Thera Solutions,Ltd.,a commercial stage biopharmaceutical company (688177.SH) and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), today announced that the companies have executeda licen...
GUANGZHOU, China & MOSCOW--(BUSINESS WIRE)--Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has reached a licensing...
GUANGZHOU, China--(BUSINESS WIRE "BAT1706 is the company's second application for marketing approval of a Biosimilar in China, following the approval of Qletli® (adalimumab injection)," said Dr. Li Shengfeng, founder and CEO of Bio-TheraSolutions. "L...
